Latest News

Natural Killer cell destroying a cancer cell

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

09/02/2021

We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.

Read More

Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications

08/12/2020

Vault CTMS and Vault eTMF provide complete visibility into trials, enabling CRO to deliver value-added services to sponsors PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents. Veeva […]

Read More

Simbec-Orion and Oncodistinct Network agreement to strengthen early phase oncology research

01/10/2020

Providing oncology drug developers with the successful delivery of early phase oncology studies. Slough, Berkshire, United Kingdom: Simbec-Orion announced a charter agreement between the Oncodistinct Network and Simbec-Orion. The agreement strengthens the relationships between Simbec-Orion and the Oncodistinct network of oncology sites, who partner in operations and scientific expertise in the design and conduct of […]

Read More

Exvastat wins a 3.6 million euro grant for COVID-19 trial

19/05/2020

Congratulations to Cambridge Innovation Capital portfolio company Exvastat that has been awarded a grant from the prestigious Innovative Medicines Initiative. The grant will be used to reformulate and study imatinib in the treatment of Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) in collaboration with Vrije Universiteit Amsterdam (VU Amsterdam), KABS Laboratories Inc. and Simbec-Orion. Read […]

Read More

Simbec-Orion Receives The โ€œCRO Of The Yearโ€ Award At 2019 European Lifestars AwardsTM

21/01/2020

Celebrating success across life sciences London, UK, November 25th 2019. Simbec-Orion is pleased to announce that it has been recognised as the winner of the CRO of the Year award at the 2019 Lifestars AwardsTM. Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such […]

Read More

Got a question?
Get in Touch or Submit an RFI/RFP


Our team is on hand to answer any questions you might have relating to the work we do at Simbec-Orion. Just fill in the form below, making sure to tick the boxes that apply, and weโ€™ll respond as quickly as we can.

Looking to volunteer for a clinical trial?

Visit our dedicated volunteer website here, or email [email protected]

Follow us on Social Media

Send us a message, weโ€™ll respond as quickly as possible

Complete the form below, and weโ€™ll get back to you as soon as possible regarding your query.

Name(Required)
Opt In Emails